



February 12, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter ended December 31, 2024 and Interim Dividend for Financial Year 2024-25

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 10.10 a.m. and ended at 2:25 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2024 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2024;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2024 furnished by Statutory Auditors of the Company.

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2024-25 of Rs. 80 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before March 7, 2025.

As informed earlier in our letter dated January 31, 2025, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 21, 2025.

Kindly take the same on record and oblige.

Thanking you.

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 31 DECEMBER 2024

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st December 2024 (Unaudited)	Preceding Three months ended 30th September 2024 (Unaudited)	Corresponding Three months ended 31st December 2023 (Unaudited)	Six months ended 31st December 2024 (Unaudited)	Six months ended 31st December 2023 (Unaudited)	Year ended 30th June 2024 (Audited)
1.	Revenue from Operations	30,977	31,341	30,997	62,318	61,490	115,126
2.	Other Income	396	328	518	724	1,123	1,563
3.	Total income (1+2)	31,373	31,669	31,515	63,042	62,613	116,689
4.	Expenses						
	a) Cost of materials consumed	6,160	4,817	7,084	10,977	15,815	29,023
	b) Purchases of stock-in-trade	1,328	2,016	840	3,344	982	3,946
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	85	1,972	1,115	2,057	956	87
	d) Employee benefits expenses	4,705	4,622	5,743	9,327	11,807	21,516
	e) Depreciation and amortisation expenses	555	577	692	1,132	1,340	2,740
	f) Finance costs	15	15	19	30	37	72
	g) Other expenses	6,356	6,510	6,050	12,866	12,899	29,954
	Total expenses (4)	19,204	20,529	21,543	39,733	43,836	87,338
5.	Profit before exceptional items and tax (3-4)	12,169	11,140	9,972	23,309	18,777	29,351
6.	Less: Exceptional items (refer note 4)	-	-	-	-	-	2,019
7.	Profit before tax (5-6)	12,169	11,140	9,972	23,309	18,777	27,332
8.	Tax expenses						
	Current Tax	2,904	2,795	2,772	5,699	5,001	7,910
	Deferred Tax Charge / (Credit)	175	112	(191)	287	(172)	(860)
	Adjustment of tax relating to earlier periods	-	-	184	-	184	184
	Total tax expenses	3,079	2,907	2,765	5,986	5,013	7,234
9.	Net Profit for the period / year (7-8)	9,090	8,233	7,207	17,323	13,764	20,098
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains / (losses) on defined benefit plans	(266)	23	115	(243)	47	90
	ii. Income tax effect	67	(6)	(29)	61	(12)	(23)
	Other Comprehensive Income, net of tax	(199)	17	86	(182)	35	67
11.	Total Comprehensive Income for the period / year (9+10)	8,891	8,250	7,293	17,141	13,799	20,165
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1,660	1,660	1,660	1,660	1,660	1,660
13.	Other equity						52,164
14.	Earnings per equity share (of ₹ 10/- each)						
	*(not annualised)						
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 54.76	* 49.60	* 43.42	* 104.36	* 82.92	133.24
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 54.76	* 49.60	* 43.42	* 104.36	* 82.92	121.07

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above unaudited results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on 12th February, 2025. The statutory auditors of the Company have carried out limited review of the above unaudited financial results and have issued an unmodified limited review report.
2. Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
3. The Board of Directors, on 23rd January, 2025, approved the change of the Financial Year ending of the Company from June 30 to March 31. Accordingly, the current Financial Year of the Company viz., 2024-25 shall be a period of nine months commencing on 01st July, 2024, and ending on 31st March, 2025.
4. During the previous year, the Company discontinued production of injections at its manufacturing plant in Goa effective 30th September, 2023, as the Company started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended 30th June, 2024 the Company entered into an agreement for sale of the assets of its injection plant for a consideration of ₹ 790 Lakhs and impaired the balance amount of ₹ 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of ₹ 1,392 Lakhs. The above total amount of ₹ 2,019 Lakhs have been disclosed as an exceptional item for the quarter and the year ended June 30, 2024. A portion of asset, pending disposal is reflected under Assets held for Sale in the balance sheet as at 31st December, 2024.
5. The Board of Directors at its meeting held on 12th February, 2025 have declared for the current year an interim dividend of ₹80 per equity share of face value ₹ 10 each aggregating to ₹13,280 lakhs.
6. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
7. The Company does not have a subsidiary, an associate or a joint venture as at 31st December, 2024.
8. The unaudited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).
9. Figures for earlier periods have been regrouped, wherever necessary.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

Milind Vasant
Thatte

Digitally signed by
Milind Vasant Thatte
Date: 2025.02.12
14:00:02 +05'30'

Milind Thatte
Managing Director

Place : Mumbai
Date : February 12, 2025

PROCTER & GAMBLE HEALTH LIMITED
Statement of Assets and Liabilities

(₹ in lakhs)

Particulars	As at December 31, 2024 (Unaudited)	As at June 30, 2024 (Audited)
<u>ASSETS</u>		
Non-current assets		
(a) Property, plant and equipment	11,016	11,721
(b) Capital work-in-progress	804	589
(c) Investment property	173	190
(d) Right -of -use assets	707	843
(e) Intangible assets	84	96
(f) Financial assets		
(i) Loans	944	974
(ii) Other financial assets	485	624
(g) Deferred tax assets (net)	3,143	3,369
(h) Other non-current assets	312	189
(i) Non-current tax assets (net)	8,098	8,419
Total non-current assets	25,766	27,014
Current assets		
(a) Inventories	11,878	10,911
(b) Financial assets		
(i) Trade receivables	13,067	8,533
(ii) Cash and cash equivalents	26,643	23,850
(iii) Bank balances other than (ii) above	629	586
(iv) Loans	157	172
(v) Other financial assets	1,954	1,337
(c) Other current assets	6,811	6,133
(d) Assets held for Sale	110	900
Total current assets	61,249	52,422
TOTAL ASSETS	87,015	79,436
<u>EQUITY AND LIABILITIES</u>		
Equity		
(a) Equity share capital	1,660	1,660
(b) Other equity	59,386	52,164
Total Equity	61,046	53,824
Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease liabilities	552	688
(b) Provisions	3,256	2,964
(c) Other non-current liabilities	169	69
Total non-current liabilities	3,977	3,721
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	958	912
- Total outstanding dues of creditors other than micro enterprises and small enterprises	16,185	15,788
(ii) Lease Liabilities	276	268
(iii) Other financial liabilities	1,821	2,301
(b) Provisions	512	1,024
(c) Current tax liabilities (net)	1,036	345
(d) Other current liabilities	1,204	1,253
Total current liabilities	21,992	21,891
Total liabilities	25,969	25,612
TOTAL EQUITY & LIABILITIES	87,015	79,436

Procter & Gamble Health Limited

Statement of Cash Flow

(₹ in lakhs)

Particulars	Six months ended December 31, 2024 (Unaudited)	Year ended June 30, 2024 (Audited)
A. Cash Flows from Operating Activities		
Profit before tax	23,309	27,332
Adjustments for:		
Net unrealised foreign exchange (Gain)/Loss	(3)	202
Allowance for doubtful receivables/ other assets	(194)	74
Inventory written off	42	270
Provision/ write off of GST and other taxes	158	1,227
Depreciation and amortization expense	1,132	2,740
Provision for Impairment	-	2,019
Rental income	(201)	(210)
Provision for employee benefits	484	705
Provision for sales return/ expiries	(441)	(819)
Loss/(Profit) on sale of property, plant and equipment	3	51
Share-based payment to employees	41	69
Finance costs	30	72
Interest income	(515)	(1,173)
Operating profit before working capital changes	23,845	32,559
Working capital adjustments:		
(Increase)/Decrease in inventories	(1,009)	2,313
(Increase)/Decrease in trade receivables	(4,335)	2,917
(Increase)/Decrease in financial and other Assets	(1,306)	1,827
Decrease/(Increase) in trade payables	366	(7,161)
(Increase)/Decrease in other liabilities and provisions	(927)	(1,108)
Cash generated from operations	16,634	31,348
Income taxes paid (net)	(4,687)	(8,519)
Net cash flows (used in) / generated from operating activities (A)	11,947	22,829
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant & equipment and Intangible assets	(533)	(2,173)
Proceeds from disposal of property plant & equipment and assets held for sale	790	14
Rental income	201	210
Interest received	506	1,262
Net cash flows (used in) / generated from investing activities (B)	964	(687)
C. Cash flow from financing activities		
Dividend paid	(9,960)	(41,499)
Payment of lease liability	(156)	(312)
Net cash flows (used in) / generated from financing activities (C)	(10,116)	(41,811)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	2,795	(19,669)
Cash and cash equivalents at the beginning of the period / year	23,873	43,542
Cash and cash equivalents at the end of the period / year	26,668	23,873
Components of Cash and Cash equivalents at the end of the period / year:		
Balance with Banks		
In Current accounts	8,668	8,873
In Term deposits (having original maturity of less than three months)	18,000	15,000
	26,668	23,873

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

Independent Auditor’s Review Report on quarter and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors of

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** (“the Company”) for the quarter ended December 31, 2024 and for the period from July 01, 2024 to December 31, 2024 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as “the said Indian Accounting Standard”) and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048

SUMANT
MANGESH
SAKHARDAND
E

Digitally signed by
SUMANT MANGESH
SAKHARDANDE
Date: 2025.02.12
14:16:06 +05'30'

Sumant Sakhardande

Partner

Membership No. 034828

UDIN: 25034828BMNZHH5576

Place: Mumbai

Date: February 12, 2025